RecruitingNCT07343089
A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France
Sponsor
University Hospital, Strasbourg, France
Enrollment
100 participants
Start Date
Aug 29, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Clinical, biological, radiological, and pharmacological description of cases of disseminated borreliosis (Borrelia burgdorferi sl. and Borrelia miyamotoi) occurring in patients who received drug treatment based on anti-CD20 monoclonal antibodies.
Eligibility
Min Age: 1 Year
Inclusion Criteria2
- Minor or adult subject
- Having presented disseminated borreliosis confirmed by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi) within 24 months of receiving treatment with an anti-CD20 monoclonal antibody between January 1, 2010, and July 30, 2025.
Exclusion Criteria1
- \- Refusal to participate in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07343089